RXRX
Recursion Pharmaceuticals Inc

14,027
Mkt Cap
$2.5B
Volume
5.62M
52W High
$12.36
52W Low
$3.79
PE Ratio
-3.22
RXRX Fundamentals
Price
$5.68
Prev Close
$5.75
Open
$5.74
50D MA
$5.19
Beta
2.48
Avg. Volume
26.92M
EPS (Annual)
-$1.69
P/B
2.71
Loading...
Loading...
News
all
press releases
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.75, marking a -5.89% move from the previous day.
Zacks·17h ago
News Placeholder
More News
News Placeholder
Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $6.36, moving 6.33% from the previous trading session.
Zacks·7d ago
News Placeholder
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $5.23, representing a -5.42% change from its previous close.
Zacks·16d ago
News Placeholder
Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains?
Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·20d ago
News Placeholder
Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.98, representing a +1.32% change from its previous close.
Zacks·1mo ago
News Placeholder
Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $4.77, signifying a -1.24% move from its prior day's close.
Zacks·1mo ago
News Placeholder
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.
Zacks·3mo ago
News Placeholder
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -17.14% and +33.71%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.
Zacks·3mo ago
News Placeholder
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3mo ago

Latest RXRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.